Patents by Inventor Jeremy M. Murray

Jeremy M. Murray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20220127265
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Therapeutic compounds and uses thereof
    Patent number: 11247989
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 15, 2022
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • ANTI RSPO ANTIBODIES AND METHODS OF USE
    Publication number: 20200199208
    Abstract: Provided herein are anti-RSPO antibodies, in particular anti-RSPO2 antibodies and/or anti-RSPO3 antibodies, and methods of using the same.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 25, 2020
    Inventors: Elaine Storm, Frederic J. de Sauvage, Jeremy M. Murray, Cameron L. Noland, Yan Wu, Christine Tan, Jo-Anne Hongo, Yongmei Chen
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20190241558
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 21, 2018
    Publication date: August 8, 2019
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • ANTI RSPO ANTIBODIES AND METHODS OF USE
    Publication number: 20180312579
    Abstract: Provided herein are anti-RSPO antibodies, in particular anti-RSPO2 antibodies and/or anti-RSPO3 antibodies, and methods of using the same.
    Type: Application
    Filed: December 11, 2017
    Publication date: November 1, 2018
    Inventors: Elaine Storm, Frederic J. de Sauvage, Jeremy M. Murray, Cameron L. Noland, Yan Wu, Christine Tan, Jo-Anne Hongo, Yongmei Chen
  • USP7 inhibitor compounds and methods of use
    Patent number: 9573899
    Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 21, 2017
    Assignee: Genentech, Inc.
    Inventors: Robert Blake, Paola Di Lello, Jason Drummond, Christine Johanna Heideker, Lorna Kategaya, Till Maurer, Jeremy M. Murray, Chudi Ndubaku, Richard Pastor, Lionel Rouge, Vickie Tsui, Ingrid E. Wertz, Kebing Yu
  • USP7 INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20160272588
    Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: March 18, 2016
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert Blake, Paola Di Lello, Jake Drummond, Christine Johanna Heideker, Lorna Kategaya, Till Maurer, Jeremy M. Murray, Chudi Ndubaku, Richard Pastor, Lionel Rouge, Vickie Tsui, Ingrid E. Wertz, Kebing Yu
  • ANTI-RSPO ANTIBODIES AND METHODS OF USE
    Publication number: 20150147333
    Abstract: Provided herein are anti-RSPO antibodies, in particular anti-RSPO2 antibodies and/or anti-RSPO3 antibodies, and methods of using the same.
    Type: Application
    Filed: October 17, 2014
    Publication date: May 28, 2015
    Applicant: GENENTECH, INC.
    Inventors: Elaine Storm, Frederic J. de Sauvage, Jeremy M. Murray, Cameron L. Noland, Yan Wu, Christine Tan, Jo-Anne Hongo, Yongmei Chen
  • Quinazolines for PDK1 inhibition
    Patent number: 7932262
    Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: April 26, 2011
    Assignee: Novartis AG
    Inventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice Rico, Xiaojong M. Wang, Rama Jain, Jeremy M. Murray, Stephen E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng
  • QUINAZOLINES FOR PDK1 INHIBITION
    Publication number: 20100048561
    Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 25, 2010
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice C. Rico, Xiaojing M. Wang, Rama Jain, Jeremy M. Murray, Steven E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng